1. Home
  2. ALXO vs LARK Comparison

ALXO vs LARK Comparison

Compare ALXO & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.99

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

N/A

Current Price

$31.84

Market Cap

196.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ALXO
LARK
Founded
2015
1885
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
205.9M
196.4M
IPO Year
2020
2001

Fundamental Metrics

Financial Performance
Metric
ALXO
LARK
Price
$1.99
$31.84
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
941.1K
7.4K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
3.07%
EPS Growth
26.36
35.84
EPS
N/A
1.70
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$18.73
Revenue Growth
N/A
N/A
52 Week Low
$0.96
$23.57
52 Week High
$2.66
$32.44

Technical Indicators

Market Signals
Indicator
ALXO
LARK
Relative Strength Index (RSI) 49.51 56.59
Support Level $1.93 $25.83
Resistance Level $2.21 $32.40
Average True Range (ATR) 0.12 0.38
MACD -0.00 -0.06
Stochastic Oscillator 38.72 70.83

Price Performance

Historical Comparison
ALXO
LARK

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.

Share on Social Networks: